Infliximab as First Line Therapy in Patients With Early Active Axial Spondyloarthritis Trial.

Trial Profile

Infliximab as First Line Therapy in Patients With Early Active Axial Spondyloarthritis Trial.

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Apr 2017

At a glance

  • Drugs Infliximab (Primary) ; Naproxen
  • Indications Spondylarthritis
  • Focus Therapeutic Use
  • Acronyms INFAST
  • Sponsors Merck Sharp & Dohme; Schering-Plough
  • Most Recent Events

    • 13 Jul 2016 Results of a post-hoc analysis published in the Rheumatology
    • 25 Mar 2016 Results published in the Arthritis and Rheumatology
    • 13 Jun 2015 Results (part I)presented at the 16th Annual Congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top